Tanabe Pharma
Founded in 1678 in Osaka, Tanabe Pharma is one of the world's oldest pharmaceutical companies and remains a prominent name in Japan's life sciences industry. In 2026, the company is attracting significant market attention through major structural transformation, strategic portfolio optimization, and a renewed focus on innovation. Following its acquisition by Bain Capital for approximately JPY 510 billion (USD 3.2 billion) and the removal of its long-standing Mitsubishi branding, Tanabe Pharma is reshaping its global footprint while strengthening its position in the Japanese market.
As part of its growth strategy, the company plans to launch up to three new drugs annually in Japan, prioritising rare diseases and high-value therapeutic areas. Tanabe Pharma is also rebuilding its development pipeline through a combination of internal research capabilities and the in-licensing of innovative medicines from overseas partners. These strategic initiatives highlight the company's transition into a more agile, innovation-driven pharmaceutical company, reinforcing its role as a key player in Japan's evolving biopharmaceutical landscape.
"Backed by Bain Capital, Tanabe Pharma is transforming its legacy into future growth by prioritizing rare diseases, domestic innovation, and strategic licensing"
Rare Disease
The National Institutes of Health (NIH) recognizes over 7,000 rare diseases, with about 95 percent lacking effective treatments. A significant number of these conditions receive limited attention from medical researchers, resulting in many patients resorting to "off-label" treatments, which are not FDA-approved for their specific condition and can create challenges with insurance coverage.
The rare disease market is both appealing and anticipated to expand rapidly. Although approximately 7,000 rare diseases have been identified, only around 130 have approved treatments available. There is a substantial unmet medical need, and existing treatments offer considerable benefits. Governance and regulatory incentives, such as expedited approval processes and enhanced protection under orphan designation, further enhance the market's attractiveness.
Projected revenue for the rare disease market (2024 - 2034)
Fig 11: Market revenue forecast of rare disease (2024 - 2034)
Market revenue of Tanabe Pharma
Formerly known as Mitsubishi Tanabe Pharma Corporation, Tanabe Pharma has demonstrated overall revenue growth over the past six years, supported by strong product sales and royalty income. The company reported ¥535.5 billion in revenue in FY2022/23, representing a nearly 40% year-on-year increase, primarily driven by substantial royalty payments. Despite this growth, profitability was adversely affected by one-time charges, including the closure of its Canadian subsidiary, Medicago. In FY2023/24, following its transition from Mitsubishi Tanabe Pharma Corporation to Tanabe Pharma Corporation, revenue declined to ¥437.4 billion, an 18.3% decrease year-on-year, while maintaining a strong commercial presence.
“Formerly Mitsubishi Tanabe Pharma, the company has maintained a strong revenue trajectory despite recent market and restructuring challenges.”
Six-years market revenue of Tanabe Pharma (2020-2025)
Fig 12: Market revenue of Tanabe Pharma
Tanabe Pharma Drug Pipeline: Strategic Transformation and Innovation
Japan's pharmaceutical sector is undergoing significant transformation, with Tanabe Pharma leading the shift. Following its $3.3 billion (¥510 billion) acquisition by Bain Capital, the company has restructured its business by divesting non-core assets to sharpen its strategic focus.
Key milestones include the $2.5 billion sale of the global Radicava (edaravone) business to Shionogi in December 2025, followed by the July 2026 divestment of its manufacturing subsidiary and 17 legacy products to Towa Pharmaceutical. These moves reflect Tanabe Pharma's transition toward a more focused, innovation-driven business model, highlighting broader trends reshaping Japan's pharmaceutical landscape.
Late-Stage Drug Pipeline Focused on Neurology and Rare Diseases
Tanabe Pharma’s pipeline is focused on neurological and autoimmune disorders, with several late-stage candidates nearing commercialisation.
- Roluperidone (MT-210) is being developed for schizophrenia and is currently under regulatory review.
- Inebilizumab (MT-0551/Uplizna) is under regulatory review for myasthenia gravis.
- ND0612, a continuous subcutaneous levodopa/carbidopa therapy for Parkinson’s disease, is advancing through Phase 3 development and regulatory filing.
- Unasnemab (MT-3921) is in Phase 2 development for spinal cord injury and Phase 1 development for HTLV-1-associated myelopathy.
- The company leverages a mix of in-house research, strategic licensing agreements, and academic collaborations to strengthen its pipeline.
- Tanabe Pharma’s R&D strategy emphasises high-value neurological and rare disease therapies, supporting long-term growth and innovation.
Strategic Immuno-Inflammation Pipeline Targeting Rare and Autoimmune Disorders
Tanabe Pharma’s immuno-inflammation pipeline is anchored by two Phase 3 programs:
- Uplizna (inebilizumab/MT-0551) for systemic sclerosis in Japan and dersimelagon (MT-7117) for erythropoietic protoporphyria and X-linked protoporphyria globally.
- Dersimelagon is also being evaluated in Phase 2 for systemic sclerosis, expanding its potential across multiple inflammatory conditions.
- The company is advancing MT-2990, a fully human anti-IL-33 monoclonal antibody, in Phase 1 development for ANCA-associated vasculitis in Japan.
- MT-3534, an antibody therapy for autoimmune diseases, is in Phase 1 development and was co-discovered with Pharma Foods International.
- The portfolio combines licensed assets, in-house innovation, and collaborative research, highlighting Tanabe Pharma’s commitment to immune-mediated and rare disease therapies.
Advancing Precision Oncology Through Targeted and Innovative Cancer Therapies
Tanabe Pharma’s oncology pipeline is focused on both hematologic cancers and solid tumors, with programs spanning early- to late-stage clinical development.
- MT-2111 (loncastuximab tesirine), an anti-CD19 antibody-drug conjugate licensed from ADC Therapeutics, is being developed for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in Japan.
- MT-2111 is in Phase 1/2 as a monotherapy and has advanced to Phase 3 in combination with rituximab, supported by an ongoing global co-development program.
- MT-4561, an in-house developed BRD4 degrader, is in Phase 1/2 global studies for advanced solid tumors.
The oncology portfolio combines strategic licensing partnerships and proprietary innovation, underscoring Tanabe Pharma’s commitment to developing targeted cancer therapies with differentiated mechanisms of action.
